U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11IN2O5
Molecular Weight 354.0985
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IDOXURIDINE

SMILES

OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C(=O)NC2=O

InChI

InChIKey=XQFRJNBWHJMXHO-RRKCRQDMSA-N
InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1

HIDE SMILES / InChI
Molecular Formula C9H11IN2O5
Molecular Weight 354.0985
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm; http://www.ncbi.nlm.nih.gov/pubmed/9336833; http://www.ncbi.nlm.nih.gov/pubmed/12705773; http://www.ncbi.nlm.nih.gov/pubmed/14435162; http://www.ncbi.nlm.nih.gov/pubmed/4309419

Idoxuridine is an antiviral agent use in keratitis caused by herpes simplex virus. As a prescription drug it comes as a 0.1% ophthalmic solution/drops (Herplex and Dendrid). The first studies of the compound for treatment of human herpes simplex started in early 1960s. Being a structural analog of thymidine idoxuridine inhibits viral DNA replication by substituting thymidine. The effect of idoxuridine results in the inability of the virus to reproduce and/or infect tissues. Idoxuridine also blocks viral thymidine kinase as its substrate analog.

CNS Activity

CNS Penetrant
2588
Curator's Comment: In rat brain

Originator

Prusoff, W.H.
3
Curator's Comment: Late 1950s

Approval Year

1963
72
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
282
Target ID: CHEMBL2366042
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
DENDRID

Approved Use

For the treatment of keratitis caused by the virus of herpes simplex.

Launch Date

1963
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
139.03 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9661893/
4538 mg/m² 1 times / day multiple, intraperitoneal
dose: 4538 mg/m²
route of administration: Intraperitoneal
experiment type: MULTIPLE
co-administered:
IDOXURIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B3-060333
http://www.3bsc.com/index/pro_info.php?id=99407
abcr GmbH
AB117388
http://www.abcr.com/shop/en/AB117388
AbMole Bioscience
M5701
http://www.abmole.com/products/idoxuridine.html
Acadechem
ACDS-064138
http://www.acadechemical.com/product/138837
Achemo Scientific Limited
AC-65310
http://www.achemo.com/search/?Keyword= 54-42-2
Achemtek
0104-021872
http://www.achemtek.com/54-42-2
Acros Organics
AC122350010
https://www.fishersci.com/shop/products/5-iodo-2-deoxyuridine-99-acros-organics/AC122350010
Acros Organics
AC122350050
https://www.fishersci.com/shop/products/5-iodo-2-deoxyuridine-99-acros-organics-2/AC122350050
Acros Organics
AC122350250
https://www.fishersci.com/shop/products/5-iodo-2-deoxyuridine-99-acros-organics-2/AC122350250
AHH Chemical co.,ltd
MB-01127
http://www.ahhchemical.com/product/MB-01127.html
AHH Chemical co.,ltd
MT-15852
http://www.ahhchemical.com/product/MT-15852.html
AK Scientific, Inc. (AKSCI)
I381
http://www.aksci.com/item_detail.php?cat=I381
Alfa Aesar
A11542
https://www.alfa.com/en/catalog/A11542/
Alfa Chemistry
AP54422
https://reagents.alfa-chemistry.com/product/idoxuridine-cas-54-42-2-12879.html
Allbio Pharm Co., Ltd
AD03974
http://www.allbiopharm.com/product/n/AD03974
Ambinter
Amb20240644
http://www.ambinter.com/reference/20240644
Angene
AGN-PC-0OC1UC
http://www.angenechemical.com/productshow/AGN-PC-0OC1UC.html
Anward
ANW-32073
http://www.anward.com/pro_result/19475
ApexBio Technology
B1773
http://www.apexbt.com/idoxuridine.html
AstaTech, Inc.
34454
http://www.astatechinc.com/CPSResult.php?CRNO=35733
Aurum Pharmatech LLC
C-1149
http://www.Aurumpharmatech.com/Product/ProductDetails/C_1149
Avantor Inc
101095-192
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-192
Avantor Inc
101188-680
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101188-680
Avantor Inc
TCI0258-25G
https://us.vwr.com/store/product/9986271/5-iodo-2-deoxyuridine-idoxuridine-99-0-by-titrimetric-analysis
BioChemPartner
BCP29428
http://www.biochempartner.com/54-42-2-BCP29428
BioSynth
J-009907
https://www.biosynth.com/en/products/all-products/products/J-009907.html
BioSynth
J-700180
https://www.biosynth.com/products/biochemistry/other-biochemicals/products/J-700180.html
BLD Pharm
BD21350
http://www.bldpharm.com/products/54-42-2.html
Capot Chemical
14202
http://www.capotchem.com/en/14202.htm
Capot Chemical
PubChem14202
http://www.capotchem.com/en/14202.htm
Chem Scene
CS-2346
http://www.chemscene.com/54-42-2.html
Chemenu
CM104566
http://www.chemenu.com/products/CM104566
ChemMol
30107503
http://www.chemmol.com/chemmol/30107503.html
ChemMol
97804673
http://www.chemmol.com/chemmol/97804673.html
Chemspace
CSSB00016987667
https://chem-space.com/CSSB00016987667
CSNpharm
CSN12762
https://www.csnpharm.com/products/idoxuridine.html
DC Chemicals
DC31184
http://www.dcchemicals.com//product_show-Idoxuridine.html
Debye Scientific
DB-009133
http://www.debyesci.com/DB-009133.html
eNovation Chemicals
D481174
http://www.enovationchem.com/productDetails.asp?productID=D481174
eNovation Chemicals
D641040
https://enovationchem.com/ProductDetails.asp?ProductID=D641040
eNovation Chemicals
D911222
https://www.enovationchem.com/ProductDetails.asp?ProductID=D911222
eNovation Chemicals
Y1001627
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1001627
eNovation Chemicals
Y1044145
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1044145
FondChemical
FDB-3203
http://www.fondchemical.com/cpshow_cid_8_pid_2479.html
Glentham Life Sciences
GP1769
http://www.glentham.com/products/product/GP1769/
iChemical
EBD3058765
http://www.ichemical.com/products/54-42-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00188566
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188566
LGC Standards
DRE-A14278800AL-100
https://www.lgcstandards.com/US/en/p/DRE-A14278800AL-100
LGC Standards
DRE-C14278800
https://www.lgcstandards.com/US/en/p/DRE-C14278800
LGC Standards
LGCFOR0791.00
https://www.lgcstandards.com/US/en/p/LGCFOR0791.00
LGC Standards
MM0791.00
https://www.lgcstandards.com/US/en/p/MM0791.00
Matrix Scientific
90262
https://www.matrixscientific.com/090262.html
mcule
MCULE-5585466189
https://mcule.com/MCULE-5585466189/
MedChem Express
HY-B0307
https://www.medchemexpress.com/Idoxuridine.html
MuseChem
I003999
https://www.musechem.com/product/I003999.html
Oakwood
92965
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=78139&ExtHyperLink=1
OChem
5970
http://www.ocheminc.com/index.php?act=psearch&pid=134I656
Parchem
29126
http://www.parchem.com/chemical-supplier-distributor/Idoxuridine-019126.aspx
Selleck Chemicals
S1883
http://www.selleckchem.com/products/idoxuridine.html
Sigma-Aldrich
1336001_USP
https://www.sigmaaldrich.com/catalog/product/usp/1336001?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
I0050000_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/i0050000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
I7125_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/i7125?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S048481
http://www.sinfoobiotech.com/product/1051879
Smolecule
S530413
http://www.smolecule.com/products/s530413
TCI (Tokyo Chemical Industry)
I0258
http://www.tcichemicals.com/eshop/en/us/commodity/I0258/index.html
THE BioTek
bt-270024
https://www.thebiotek.com/product/inhibitors/bt-270024
VladaChem
VL262525-1G
https://www.vladachem.com/product.php?products=54-42-2
PubMed

PubMed

TitleDatePubMed
5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
2007-11-15
IPdR: a novel oral radiosensitizer.
2007-09
Overexpression of p27 Kip 1, probability of cell cycle exit, and laminar destination of neocortical neurons.
2005-09
Effects of single-pulse (< or = 1 ps) X-rays from laser-produced plasmas on mammalian cells.
2004-12
Synthesis and antiviral activities of 1'-carbon-substituted 4'-thiothymidines.
2004-10-15
[Therapeutic effect of 125IUdR on the glioma cell line C6 in vitro and in vivo].
2004-09
Synchrotron radiation-based experimental determination of the optimal energy for cell radiotoxicity enhancement following photoelectric effect on stable iodinated compounds.
2004-08-02
Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications.
2004-08
Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
2004-08
New tertiary constraints between the RNA components of active yeast spliceosomes: a photo-crosslinking study.
2004-08
Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.
2004-07-19
Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
2004-07-15
Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2'-deoxy-2'-(fluoromethylene) cytidine and iododeoxyuridine.
2004-07
Antiviral drugs in current clinical use.
2004-06
Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts.
2004-05-20
Polyphosphoinositides-dependent regulation of the osteoclast actin cytoskeleton and bone resorption.
2004-05-13
[The latest in herpes simplex keratitis therapy].
2004-05
Indian hedgehog: a mechanotransduction mediator in condylar cartilage.
2004-05
The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.
2004-05
In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.
2004-04
Antisense thymidylate synthase electrogene transfer to increase uptake of radiolabeled iododeoxyuridine in a murine model.
2004-03
Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk.
2004-03
Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice.
2004-02-18
In vivo comparison of IVDU and IVFRU in HSV1-TK gene expressing tumor bearing rats.
2004-01
Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
2004-01
Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.
2004
Postherpetic neuralgia.
2003-12
Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
2003-12
Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors.
2003-10-21
Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver.
2003-10
Role of MutSalpha in the recognition of iododeoxyuridine in DNA.
2003-09-01
Efficient one-step Suzuki arylation of unprotected halonucleosides, using water-soluble palladium catalysts.
2003-08-22
Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans.
2003-08-04
Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.
2003-08
Exploration of the influence of 5-iodo-2'-deoxyuridine incorporation on the structure of d[CACG(IDU)G].
2003-08
Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent.
2003-07
Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine.
2003-06-20
Postherpetic neuralgia.
2003-06
Biliary obstruction reduces hepatic killing and phagocytic clearance of circulating microorganisms in rats.
2003-05-24
A simple and efficient method for synthesis of 5-substituted 2'-deoxyuridine nucleosides using metal-halogen exchange reaction of 5-iodo-2'-deoxyuridine sodium salt.
2003-05-07
Clinical significance of atomic inner shell ionization (ISI) and Auger cascade for radiosensitization using IUdR, BUdR, platinum salts, or gadolinium porphyrin compounds.
2003-03-15
Randomized, open-labelled comparison between an idoxuridine 10% gel and acyclovir 5% cream in recurrent herpes labialis.
2003-03
Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
2003-02-15
[Anti-herpetic chemotherapeutic drugs].
2003-02
A balanced deoxyribonucleoside mixture increased the rate of DNA incorporation of 5-[125I]Iodo-2'-deoxyuridine in glioblastoma cells.
2003-02
Novel agents and strategies to treat herpes simplex virus infections.
2003-02
Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine.
2003-02
In vitro activity of potential anti-poxvirus agents.
2003-01
Interventions for herpes simplex virus epithelial keratitis.
2003
Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus.
1976-03
Patents

Patents

05830653
3
07541444
3
07771973
8
JP2000007581A
3
JP2000505435A
7
JP2005528334A
4
JPS62153296A
3

Sample Use Guides

In Vivo Use Guide
1 drop (0.1% solution) every hour
Route of Administration: Topical
In Vitro Use Guide
Antiviral susceptibility of herpes simplex viruses by idoxuridine was studied in human culture cell line WI-38. Eight concentrations were tested, beginning with 1000 ug/ml and subsequent serial one-fourth dilutions. Mean MIC was 0.5 mg/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:47:40 GMT 2025
Edited
by admin
on Mon Mar 31 17:47:40 GMT 2025
Record UNII
LGP81V5245
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DENDRID
Preferred Name English
IDOXURIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
SK&F-14287
Code English
IDOXURIDINE [WHO-IP]
Common Name English
IDOXURIDINE [MART.]
Common Name English
idoxuridine [INN]
Common Name English
IDOXURIDINE [HSDB]
Common Name English
ALLERGAN211
Code English
JODDEOXIURIDIN
Common Name English
IDOXURIDINE [USP MONOGRAPH]
Common Name English
IDOXURIDINE [USP IMPURITY]
Common Name English
SK&F 14287
Code English
IDU
Common Name English
IDOXURIDINUM [WHO-IP LATIN]
Common Name English
IDOXURIDINE [EP MONOGRAPH]
Common Name English
NSC-39661
Code English
HERPLEX
Brand Name English
STOXIL
Brand Name English
ALLERGAN-211
Code English
IODODEOXYURIDINE
Systematic Name English
IDOXURIDINE [VANDF]
Common Name English
5IUDR
Code English
IDOXURIDINE [USP-RS]
Common Name English
5-IODO-2'-DEOXYURIDINE
Systematic Name English
IDOXURIDINE [MI]
Common Name English
URIDINE, 2'-DEOXY-5-IODO-
Systematic Name English
2'-DEOXY-5-IODOURIDINE
Systematic Name English
Idoxuridine [WHO-DD]
Common Name English
5-IUDR
Code English
IDOXURIDINE [ORANGE BOOK]
Common Name English
IDOXURIDINE [JAN]
Common Name English
2'-DESOXY-5-IODOURIDINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1557
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-VATC QJ05AB02
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-ATC S01AD01
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-ATC J05AB02
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
NDF-RT N0000175466
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-ATC D06BB01
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
NCI_THESAURUS C281
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
FDA ORPHAN DRUG 95696
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-VATC QS01AD01
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
WHO-VATC QD06BB01
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
Code System Code Type Description
NSC
39661
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
SMS_ID
100000083677
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
INN
1486
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
IDOXURIDINE
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder. Solubility: Slightly soluble in water, ethanol (~750 g/l) TS and hydrochloric acid (~70 g/l) TS; freely soluble in sodium hydroxide(~80 g/l) TS. Category: Anti-infective agent. Storage: Idoxuridine should be kept in a well-closed container, protected from light. Labeling: The designation Idoxuridine for sterile non-injectable use indicates that the substance complies with the additional requirement and may be used for sterile applications. Expiry date.Additional information: Melting temperature, about 180?C, with decomposition. Requirement: Idoxuridine contains not less than 98.0% and not more than 101.0% of C9H11IN2O5, calculated with reference to the dried substance.
DAILYMED
LGP81V5245
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
EPA CompTox
DTXSID2045238
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
FDA UNII
LGP81V5245
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
DRUG BANK
DB00249
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
HSDB
7479
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
PUBCHEM
5905
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
MESH
D007065
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
DRUG CENTRAL
1417
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
MERCK INDEX
m6201
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
200-207-8
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
EVMPD
SUB08117MIG
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
RS_ITEM_NUM
1336001
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
CHEBI
147675
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
RXCUI
5653
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY RxNorm
CAS
54-42-2
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
NCI_THESAURUS
C563
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
ChEMBL
CHEMBL788
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
WIKIPEDIA
IDOXURIDINE
Created by admin on Mon Mar 31 17:47:40 GMT 2025 , Edited by admin on Mon Mar 31 17:47:40 GMT 2025
PRIMARY
Related Record Type Details
Structure of IDOXURIDINE I-125
LABELED -> NON-LABELED
Structure of IDOXURIDINE MONOHYDRATE
SOLVATE->ANHYDROUS
Structure of IDOXURIDINE I-131
LABELED -> NON-LABELED
Structure of IDOXURIDINE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of IDOXURIDINE I-124
LABELED -> NON-LABELED
Related Record Type Details
Structure of ROPIDOXURIDINE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of IDOXURIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966